RenovoRx (RNXT) Preferred Stock Liabilities (2020 - 2026)
RenovoRx (RNXT) posted Preferred Stock Liabilities of $701000.0 for Q1 2026, up 16.06% sequentially from $604000.0 in Q4 2025, and down 25.03% YoY from $935000.0 in Q1 2025.
RenovoRx (RNXT) Preferred Stock Liabilities (2020 - 2026) Analysis & Trends
RenovoRx has reported Preferred Stock Liabilities for 5 years, with the latest figure at $701000.0 in Q1 2026.
- Quarterly Preferred Stock Liabilities fell 25.03% year-over-year to $701000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $701000.0 (down 25.03% YoY) and the FY2025 annual result came in at $604000.0, down 60.24% from the prior year.
- Preferred Stock Liabilities grew to $701000.0 in Q1 2026 per RNXT's latest filing, from $604000.0 in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $3.4 million in Q2 2023 and troughed at $604000.0 in Q4 2025.
- A 4-year average of $1.6 million and a median of $1.4 million in 2024 frame the typical range for Preferred Stock Liabilities.
- The widest YoY moves for Preferred Stock Liabilities: up 6.57% in 2025, down 60.24% in 2025.
- Over 4 years, Preferred Stock Liabilities stood at $3.3 million in 2023, then plunged by 53.84% to $1.5 million in 2024, then tumbled by 60.24% to $604000.0 in 2025, then increased by 16.06% to $701000.0 in 2026.
- According to Business Quant data, Preferred Stock Liabilities over the past three periods registered $701000.0, $604000.0, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | RenovoRx | 61.96 Mn | 61.96 Mn | 766,000.00 | 350,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 350,000.00 |
| Mar 31, 2026 | 701,000.00 |
| Dec 31, 2025 | 604,000.00 |
| Sep 30, 2025 | 1.11 Mn |
| Jun 30, 2025 | 1.29 Mn |
| Mar 31, 2025 | 935,000.00 |
| Dec 31, 2024 | 1.52 Mn |
| Sep 30, 2024 | 1.19 Mn |
| Jun 30, 2024 | 1.42 Mn |
| Mar 31, 2024 | 1.93 Mn |
| Dec 31, 2023 | 3.29 Mn |
| Sep 30, 2023 | 1.91 Mn |
| Jun 30, 2023 | 3.43 Mn |
| Dec 31, 2020 | 12.45 Mn |